Breaking News Instant updates and real-time market news.

SNAP

Snap

$15.57

0.31 (2.03%)

, SFIX

Stitch Fix

$28.10

-0.835 (-2.89%)

09:12
07/12/19
07/12
09:12
07/12/19
09:12

Fly Intel: Pre-market Movers

HIGHER: Milacron (MCRN), up 21% after announcing a definitive agreement to be acquired by Hillenbrand (HI) in a cash and stock transaction valued at approximately $2B, including net debt... Hookipa Pharma (HOOK), up 29% after FDA clearance of the IND application for a clinical trial of HB-201... Snap (SNAP), up 3% after Goldman Sachs analyst Heath Terry upgraded shares to Buy from Neutral and raised his price target for the shares to $18 from $13... Stitch Fix (SFIX), up 5% after Goldman's Terry upgraded the stock to Buy from Neutral with an unchanged price target of $38... MediciNova (MNOV), up 8% after announcing its plans for a Phase 3 clinical trial of MN-166 in progressive multiple sclerosis following feedback from the FDA. LOWER: CannTrust (CTST), down 11% after Eight Capital analyst Graeme Kreindler downgraded shares to Sell from Neutral and cut his price target for the shares to C$4 from C$6. The analyst downgraded the shares to Neutral on July 8... Emcore (EMKR), down 17% after cutting Q2 guidance... Illumina (ILMN), down 14% after cutting its FY19 outlook... PNM Resources (PNM), down 3% after cutting its Q2 and FY19 EPS view... Brookfield Infrastructure (BIP), down 3% after a 11.765M share spot secondary priced at $42.50 per share.

SNAP

Snap

$15.57

0.31 (2.03%)

SFIX

Stitch Fix

$28.10

-0.835 (-2.89%)

ILMN

Illumina

$363.55

-9.15 (-2.46%)

PNM

PNM Resources

$50.38

-0.235 (-0.46%)

MCRN

Milacron

$13.54

-0.395 (-2.84%)

HI

Hillenbrand

$38.83

-0.46 (-1.17%)

HOOK

Hookipa Pharma

$6.66

-0.09 (-1.33%)

MNOV

MediciNova

$9.10

-0.01 (-0.11%)

CTST

CannTrust

$3.10

-0.06 (-1.90%)

EMKR

Emcore

$3.26

-0.09 (-2.69%)

BIP

Brookfield Infrastructure

$43.95

-0.64 (-1.44%)

  • 12

    Jul

  • 12

    Jul

  • 15

    Jul

  • 16

    Jul

  • 18

    Jul

  • 23

    Jul

  • 29

    Jul

  • 02

    Aug

  • 02

    Aug

  • 06

    Aug

  • 08

    Aug

  • 03

    Sep

  • 12

    Jul

SNAP Snap
$15.57

0.31 (2.03%)

07/09/19
FBCO
07/09/19
NO CHANGE
Target $18
FBCO
Outperform
Snap price target raised to $18 from $15 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Snap to $18 from $15 while keeping an Overweight rating on the shares. The stock closed Monday down 9c to $15.14. The analyst calculates that the number of Snap ads per session remains at ~0.3. Even if 80% of the sessions are spent on chat versus the Discover page, this still implies that Snap is showing less than two ads per session on average, Ju tells investors in a research note. This suggests there remains "significant room" for the company to increase the ad load in pursuit of revenue growth, contends the analyst.
07/11/19
BOFA
07/11/19
NO CHANGE
Target $17
BOFA
Neutral
Snap price target raised to $17 from $12 at BofA/Merrill
BofA/Merrill analyst Justin Post raised his price target for Snap to $17 from $12 ahead of the company's Q2 results while keeping a Neutral rating on the name. Snap's "gender-face-swap" filter went viral in May and its SnapKit app "Yolo" reached number one on the iOS download charts, Post tells investors in a pre-earnings research note. Further, third party Snap app data in Q2 suggests downloads were near record levels, adds the analyst. However, for advertisers, channel checks remains mixed, says Post. The analyst expects improving user trends and revenue upside in Q2, but he thinks Snap will remain conservative in its outlook.
07/01/19
MOFT
07/01/19
NO CHANGE
Target $10
MOFT
Neutral
MoffettNathanson sees 'massive' upside DAU surprise at Snap, ups target to $10
MoffettNathanson analyst Michael Nathanson raised his price target on Snap to $10 from $8 as he increased his 2020 revenue estimate by 9% to account for projecting stronger user growth due to "impressive trends" from the Snapchat Ads manager. While Nathanson said he believes that "Snap is on the verge of writing their own 'Cinderella Story' due to the likelihood of a massive upside surprise in DAU growth" in Q2 and raised his 2019 total DAU estimate by 21M to 223M, he keeps a Neutral rating on the stock, citing valuation and concerns that the market is overestimating operating leverage.
07/12/19
GSCO
07/12/19
UPGRADE
Target $18
GSCO
Buy
Snap upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Heath Terry upgraded Snap to Buy from Neutral and raised his price target for the shares to $18 from $13. The stock closed Thursday up 31c to $15.57. The company's new Android app, the launch of Snap Games and new viral lenses should accelerator user growth, Terry tells investors in a research note. He points out that Snap's total app downloads for May, the first month reflecting these recent innovations, was a record 41M. This represents a "stark reversal" of what were otherwise multi-year lows in app downloads that the platform experienced through most of 2018 and early 2019, says the analyst.
SFIX Stitch Fix
$28.10

-0.835 (-2.89%)

07/02/19
RBCM
07/02/19
NO CHANGE
Target $43
RBCM
Outperform
Stitch Fix price target lowered to $43 from $52 at RBC Capital
RBC Capital analyst Mark Mahaney lowered his price target for Stitch Fix (SFIX) to $43 from $52 and reiterated a Market Outperform rating. In a research note to investors, the analyst says is he incrementally positive on Stitch Fix following his firm's second survey of over 2,000 consumers, including around 150 Stitch Fix customers, saying there appears to be growing interest in Online clothing subscription services and the two services within this category that are most frequently used are Amazon Wardrobe (AMZN) and Stitch Fix. While the survey results are positive for Stitch Fix, Mahaney says they also clearly highlihgt the competitive risk of Amazon.
07/01/19
NEED
07/01/19
INITIATION
NEED
Hold
Stitch Fix initiated with a Hold at Needham
Needham analyst Rick Patel started Stitch Fix with a Hold rating and no price target. There's a lot to like about the company but expectations have risen following the recent stock rally and visibility on U.K. investment spend is low, Patel tells investors in a research note. As a result, the analyst prefers to wait for a better entry point or greater conviction on the potential for upside to estimates.
06/06/19
RHCO
06/06/19
NO CHANGE
Target $44
RHCO
Buy
Stitch Fix price target raised to $44 at SunTrust after 'strong' Q3 results
SunTrust analyst Youssef Squali nudged his price target on Stitch Fix higher to $44 from $43 and kept his Buy rating after its "strong" Q3 results and Q4 guidance. The analyst cites the company's improved existing customer retention along with a "healthy" growth of new active clients and believes that the management's raised outlook is "sustainable". Squali further points to the high percentage of short interest in Stitch Fix float that should drive its shares higher in the short term and its continued margin expansion supporting the stock over the longer run.
07/12/19
GSCO
07/12/19
UPGRADE
Target $38
GSCO
Buy
Stitch Fix upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Heath Terry upgraded Stitch Fix to Buy from Neutral with an unchanged price target of $38. The analyst sees a "more compelling" risk/reward in the company's ability to "lean into" its existing core customer base while also "efficiently" expanding to new categories and geographies. Recent developments in product that enable existing users to order additional colors, prints, and sizes of items they have already purchased should be a tailwind for Stitch Fix's wallet share, Terry tells investors in a research note.
ILMN Illumina
$363.55

-9.15 (-2.46%)

07/12/19
JPMS
07/12/19
NO CHANGE
JPMS
Overweight
Illumina selloff an opportunity for longer term investors, says JPMorgan
While last night's preannouncement is "clearly disappointing," Illumina remains one of the best-positioned secular growth stories in the space, JPMorgan analyst Tycho Peterson tells investors in a research note. The analyst encourages longer-term investors to take advantage of today's share weakness and keeps an Overweight rating on the name. He admits, however, that the stock will likely remain under near-term pressure pending better visibility on a 2020 recovery.
07/12/19
BOFA
07/12/19
DOWNGRADE
Target $290
BOFA
Underperform
Illumina downgraded to Underperform from Buy at BofA/Merrill
BofA/Merrill analyst Derik de Bruin double downgraded Illumina to Underperform from Buy and lowered his price target for the shares to $290 from $355. The analyst views last night's preannounced miss as surprising given management's positive commentary. He now sees limited visibility and few near-term catalysts for the shares.
07/12/19
COWN
07/12/19
NO CHANGE
Target $320
COWN
Outperform
Illumina price target lowered to $320 from $380 at Cowen
Cowen analyst Doug Schenkel lowered his price target for Illumina to $320 from $380 following the company's "huge" second quarter miss and fiscal year guidance reduction. In a research note to investors, Schenkel says while expectations for the quarter weren't high, "we didn't see a $50M miss coming," adding that the FY guidance cut is "notable." While he says the bias could be to the upside, he contends that Illumina "doesn't get the benefit of the doubt" given recent execution. He maintains an Outperform rating.
07/12/19
LEHM
07/12/19
NO CHANGE
Target $340
LEHM
Overweight
Illumina new guidance may prove conservative, says Barclays
Barclays analyst Jack Meehan calls the magnitude of Illumina's Q2 miss "very disappointing" but keeps an Overweight rating on the shares. He lowered his price target for the stock to $340 from $370. Given underlying funding and the transitory nature of the Q2 issues, the new guidance could prove conservative, Meehan tells investors in a research note.
PNM PNM Resources
$50.38

-0.235 (-0.46%)

06/12/19
UBSW
06/12/19
UPGRADE
Target $50
UBSW
Neutral
PNM Resources upgraded to Neutral from Sell at UBS
UBS analyst Rose-Lynn Armstrong upgraded PNM Resources to Neutral from Sell and raised her price target for the shares to $50 from $46.
05/10/19
MZHO
05/10/19
UPGRADE
Target $49.5
MZHO
Buy
PNM Resources upgraded to Buy from Neutral at Mizuho
Mizuho analyst Paul Fremont upgraded PNM Resources to Buy from Neutral and raised his price target for the shares to $49.50 from $43.50. The analyst sees incremental earnings upside from the Energy Transition Act adopted into New Mexico law in March. Given the "strong" political preference in New Mexico for renewables, PNM is likely to see potential spending levels rise, Fremont tells investors in a research note.
04/25/19
BOFA
04/25/19
UPGRADE
BOFA
Neutral
PNM Resources upgraded to Neutral from Underperform at BofA/Merrill
04/25/19
04/25/19
UPGRADE
Target $48

Neutral
PNM Resources upgraded to Neutral at BofA/Merrill
As previously reported, BofA/Merrill upgraded PNM Resources to Neutral from Underperform and maintained a $48 price target. Analyst Julien Dumoulin-Smith believes relative share underperformance is overdone and expects the company to execute on its capex plan.
MCRN Milacron
$13.54

-0.395 (-2.84%)

04/02/19
BARD
04/02/19
NO CHANGE
Target $21
BARD
Outperform
China data, plastics trends positive indicators for Milacron, says Baird
Baird analyst Michael Halloran noted that China's core PMI improved sequentially for the second consecutive month in March and that February's Plastics Processors Index remained in expansionary territory. Taking both data points together gives him incremental confidence that Milacron's underlying estimates are achievable in 2019, Halloran tells investors. The analyst, who thinks Milacron's core franchise value is underappreciated, keeps an Outperform rating and $21 price target on the shares.
04/17/19
KEYB
04/17/19
NO CHANGE
KEYB
Ametek, ITT among top potential acquirers in industrial space, says KeyBanc
KeyBanc analysts Jeff Hammond and Steve Barger think moderating organic growth expectations in 2019 due to tough year over year comps may drive industrials to increasingly look toward inorganic avenues for market outgrowth, or to potentially divest businesses to right-size portfolios. The analysts view Ametek (AME), ITT (ITT), Graco (GGG), and Timken (TKR) as the top potential acquirers, and think Actuant (ATU), Colfax (CFX), Eaton (ETN), Kaman (KAMN), NN, Inc. (NNBR), and Milacron (MCRN) could benefit most from a strategic divestiture.
HI Hillenbrand
$38.83

-0.46 (-1.17%)

05/21/19
05/21/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Uber (UBER) initiated with an Equal Weight at Consumer Edge and a Neutral at Susquehanna. 2. Incyte (INCY) initiated with a Neutral at Credit Suisse. 3. Hillenbrand (HI) initiated with a Neutral at DA Davidson. 4. Target Hospitality (TH) initiated with a Buy at Deutsche Bank. 5. Jack in the Box (JACK) reinstated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/21/19
05/21/19
INITIATION
Target $43

Neutral
Hillenbrand initiated with a Neutral at DA Davidson
As previously reported, DA Davidson analyst Matt Summerville initiated Hillenbrand with a Neutral rating and a price target of $43. The analyst notes that the all-time record backlog in the company's Process Equipment Group segment supports its mid-single-digit organic growth, with "large plastics projects" as well as high win rates and share gains, but sees its Batesville segment facing "long-term secular challenges" with volume erosion driven margin pressure. While Summerville remains positive on Hillenbrand's "healthy" balance sheet and M&A appetite, he warns that the company's Batesville segment may see low-single-digit organic sales decline in each year of his outlook.
05/20/19
DADA
05/20/19
INITIATION
Target $43
DADA
Neutral
Hillenbrand initiated with a Neutral at DA Davidson
DA Davidson initiated Hillenbrand with a Neutral and $43 price target.
05/16/19
05/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Jefferies starts 'underappreciated' Par Technology (PAR) with Buy rating. 2. Ichor Holdings (ICHR) initiated with a Buy at B. Riley FBR. 3. T2 Biosystems (TTOO) initiated with a Buy at Alliance Global Partners. 4. CV Sciences (CVSI) initiated with a Buy at Roth Capital. 5. Hillenbrand (HI) initiated with a Buy at Buckingham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
HOOK Hookipa Pharma
$6.66

-0.09 (-1.33%)

05/13/19
RBCM
05/13/19
INITIATION
Target $23
RBCM
Outperform
Hookipa Pharma initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams initiated Hookipa Pharma with an Outperform rating and a price target of $23. The analyst believes that the vaccines from the company's arenavirus platform could yield an "optimal immune upregulation" in the treatment and prevention of infectious diseases, and expects these to "drive considerable long-term value as they mature." Abrahams also cites the platform's "validation" in Hookipa's partnership with Gilead that should lead to "monetization" of the company's technology.
05/13/19
BOFA
05/13/19
INITIATION
BOFA
Buy
Hookipa Pharma initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Ying Huang initiated Hookipa Pharma with a Buy and $17 price target saying it is leveraging arenavirus to develop broad, antigen-specific immune responses to deliver antigens to dendritic cells in the blood. Huang said Hookipa has a broad intellectual property position and this arenavirus segment potentially provides an endless combination of full-length antigens that can direct immune responses to a broad range of diseases.
MNOV MediciNova
$9.10

-0.01 (-0.11%)

03/25/19
RILY
03/25/19
INITIATION
Target $22
RILY
Buy
MediciNova asumed with a Buy at B. Riley FBR
B. Riley FBR analyst Chad Mabry assumed coverage of MediciNova with a Buy rating and $22 price target.
CTST CannTrust
$3.10

-0.06 (-1.90%)

07/12/19
07/12/19
DOWNGRADE

CannTrust downgraded to Sell from Neutral at Eight Capital
Eight Capital analyst Graeme Kreindler downgraded CannTrust Holdings to Sell from Neutral and cut his price target for the shares to C$4 from C$6. The analyst downgraded the shares to Neutral on July 8.
07/08/19
BOFA
07/08/19
DOWNGRADE
Target $3.5
BOFA
Underperform
BofA double downgrades CannTrust to Underperform after Health Canada probe
BofA Merrill Lynch analyst Christopher Carey downgraded CannTrust two notches, to Underperform from Buy, and halved his price target on the shares $3.50 from $7 after the company announced that an audit from Health Canada found it had cultivated cannabis in rooms not yet licensed to do so and put a freeze on some of the company's inventory. Even following this morning's slide he expects the stock to remain weak due to uncertainty on the impact of the probe on CannTrust's financials as well as due to likely diminished investor confidence, said Carey. In morning trading in New York, CannTrust shares are down 92c, or 19%, to $4.02.
07/09/19
ROTH
07/09/19
DOWNGRADE
Target $4
ROTH
Neutral
CannTrust downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Scott Fortune downgraded CannTrust to Neutral from Buy, noting that the company has taken a "huge credibility hit" from the issued Health Canada non-compliance rating audit report, in which Health Canada has placed a hold on about 5,200 kg of dried cannabis. To be determined is Health Canada's enforcement response to what he deems a "flagrant lack of compliance" surrounding cultivating cannabis in five unlicensed rooms over a five-month timeframe. The analyst believes the operations misstep will have material impact to financials. Fortune also lowered his price target on the shares to $4 from $8.50.
07/08/19
07/08/19
DOWNGRADE

CannTrust downgraded to Neutral from Buy at Eight Capital
Eight Capital analyst Graeme Kreindler earlier today downgraded CannTrust Holdings to Neutral from Buy and lowered his price target for the shares to C$6 from C$11.
EMKR Emcore
$3.26

-0.09 (-2.69%)

07/12/19
LSCM
07/12/19
NO CHANGE
Target $5
LSCM
Buy
Emcore target lowered to $5 after negative preannouncement at Lake Street
Lake Street analyst Jaeson Schmidt lowered his price target for Emcore to $5 from $6 following last night's negative preannouncement. The analyst, while disappointed in the company's recent execution, still thinks the opportunity in its navigation business remains. Therefore, he keeps a Buy rating on the shares.
04/02/19
RILY
04/02/19
UPGRADE
Target $5.45
RILY
Buy
Emcore upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst David Kang upgraded Emcore to Buy from Neutral with a $5.45 price target.
06/10/19
LSCM
06/10/19
NO CHANGE
LSCM
Emcore acquisition may be being underestimated, says Lake Street
Lake Street analyst Jaeson Schmidt reiterated a Buy rating and $6 price target on Emcore, and raised his FY19 and FY20 estimates on the stock, as a result of the company's acquisition of Squadron Donner Inertial for $25.8M. Schmidt added that he believes investors may be underestimating the impact of the acquisition, as he sees it helping to drive improving earnings leverage.
12/06/18
LSCM
12/06/18
NO CHANGE
Target $6
LSCM
Buy
Emcore challenges behind after 'strong' guidance, says Lake Street
Lake Street analyst Jaeson Schmidt reiterates a Buy rating on Emcore with a $6 price target citing the company's "strong" Q1 guidance. The challenges Emcore faced in fiscal 2019 are now behind the company, and it is set to return to "solid" top line growth in fiscal 2019, Schmidt tells investors in a research note. At current valuation multiples, the analyst thinks "there should be a relatively high floor on shares in the near-term."
BIP Brookfield Infrastructure
$43.95

-0.64 (-1.44%)

07/01/19
STFL
07/01/19
DOWNGRADE
STFL
Hold
Genesee & Wyoming downgraded to Hold from Buy at Stifel
Stifel analyst Michael Baudendistel downgraded Genesee & Wyoming (GWR) to Hold from Buy after the company agreed to be acquired and taken private by Brookfield Infrastructure Partners (BIP) and its institutional partners. The deal requires two-thirds approval by shareholders, but he sees approval as likely given that the acquisition price is a 39.5% premium to where shares traded before media reports regarding a deal, Baudendistel noted.
07/11/19
LEHM
07/11/19
INITIATION
Target $46
LEHM
Equal Weight
Brookfield Infrastructure initiated with an Equal Weight at Barclays
Barclays analyst Moses Sutton started Brookfield Infrastructure Partners with an Equal Weight rating and $46 price target. After nearly a decade of double-digit distribution growth, the company's scale has reached a point where its growth profile is "increasingly re-rating" closer to the bottom of its targeted distribution growth range of 5%-9%, Sutton tells investors in a research note.
04/25/19
FBCO
04/25/19
DOWNGRADE
Target $46
FBCO
Neutral
Brookfield Infrastructure downgraded to Neutral at Credit Suisse
As previously reported, Credit Suisse analyst Andrew Kuske downgraded Brookfield Infrastructure to Neutral from Outperform, with a $46 price target, given the more limited return to target and the balancing of funding needs. The analyst notes that the most interesting near-term issue facing Brookfield Infrastructure Partners is pending close for Brookfield's (BAM) Infrastructure Fund IV likely landing around $20B.
04/25/19
FBCO
04/25/19
DOWNGRADE
FBCO
Neutral
Brookfield Infrastructure downgraded to Neutral from Outperform at Credit Suisse

TODAY'S FREE FLY STORIES

HON

Honeywell

$171.68

2.87 (1.70%)

, BAESY

BAE Systems

$0.00

(0.00%)

12:08
07/18/19
07/18
12:08
07/18/19
12:08
Hot Stocks
BAE Systems names Travis Garriss as CIO, Alice Eldridge as general counsel »

BAE Systems (BAESY)…

HON

Honeywell

$171.68

2.87 (1.70%)

BAESY

BAE Systems

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

TEVA

Teva

$7.74

-0.37 (-4.56%)

, MYL

Mylan

$17.69

-0.225 (-1.26%)

12:07
07/18/19
07/18
12:07
07/18/19
12:07
Recommendations
Teva, Mylan, Novartis analyst commentary  »

Novartis' Sandoz…

TEVA

Teva

$7.74

-0.37 (-4.56%)

MYL

Mylan

$17.69

-0.225 (-1.26%)

NVS

Novartis

$93.64

3.53 (3.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 22

    Jul

  • 23

    Jul

  • 31

    Jul

  • 07

    Aug

  • 25

    Sep

CNPOF

Canopy Rivers

$0.00

(0.00%)

, CGC

Canopy Growth

$35.53

-1.04 (-2.84%)

12:06
07/18/19
07/18
12:06
07/18/19
12:06
On The Fly
Rising High: An exclusive talk with cannabis VC investor Canopy Rivers »

In this edition of…

CNPOF

Canopy Rivers

$0.00

(0.00%)

CGC

Canopy Growth

$35.53

-1.04 (-2.84%)

MCD

McDonald's

$214.02

0.27 (0.13%)

APHA

Aphria

$6.37

-0.19 (-2.90%)

ACB

Aurora Cannabis

$6.97

-0.43 (-5.81%)

CVSI

CV Sciences

$0.00

(0.00%)

CTST

CannTrust

$2.69

-0.16 (-5.61%)

CRON

Cronos Group

$14.67

-0.32 (-2.13%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.36

-0.07 (-4.90%)

TLRY

Tilray

$42.74

-1.48 (-3.35%)

TCNNF

Trulieve Cannabis

$0.00

(0.00%)

ZYNE

Zynerba

$11.72

0.045 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Jul

  • 01

    Aug

  • 08

    Aug

  • 19

    Sep

12:05
07/18/19
07/18
12:05
07/18/19
12:05
Conference/Events
Morgan Stanley pharmaceuticals analysts to hold analyst/industry conference call »

Analysts, along with DC…

QURE

uniQure

$72.65

0.38 (0.53%)

12:05
07/18/19
07/18
12:05
07/18/19
12:05
Options
uniQure call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 09

    Sep

MIRM

Mirum Pharmaceuticals

$0.00

(0.00%)

12:03
07/18/19
07/18
12:03
07/18/19
12:03
Syndicate
Breaking Syndicate news story on Mirum Pharmaceuticals »

Mirum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

FNMA

Fannie Mae

$0.00

(0.00%)

, FMCC

Freddie Mac

$0.00

(0.00%)

12:01
07/18/19
07/18
12:01
07/18/19
12:01
Periodicals
Fannie, Freddie overhaul delayed until September, Reuters says »

According to a story out…

FNMA

Fannie Mae

$0.00

(0.00%)

FMCC

Freddie Mac

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUBGY

Publicis

$0.00

(0.00%)

11:54
07/18/19
07/18
11:54
07/18/19
11:54
Earnings
Publicis reports Q2 net revenue EUR 2.23B vs. EUR 2.2B last year »

Reports Q2 EPS EUR 1.98…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

AETI

American Electric Tech.

$0.79

-0.5904 (-42.63%)

11:52
07/18/19
07/18
11:52
07/18/19
11:52
Hot Stocks
American Electric Tech. drops after stockholders approve share exchange »

Shares of American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VWAGY

Volkswagen

$0.00

(0.00%)

11:51
07/18/19
07/18
11:51
07/18/19
11:51
Hot Stocks
Volkswagen to end production of Golf Alltrack and Golf SportWagen in 2019 »

Volkswagen of America…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUBGY

Publicis

$0.00

(0.00%)

11:50
07/18/19
07/18
11:50
07/18/19
11:50
Earnings
Publicis sees second half revenue 'broadly stable' on organic basis »

Publicis said when…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

SMH

Market Vectors Semiconductor

$114.90

0.53 (0.46%)

11:50
07/18/19
07/18
11:50
07/18/19
11:50
Options
Semiconductor ETF call volume 6x normal on 4-way roll from July to Aug »

Semiconductor ETF call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:50
07/18/19
07/18
11:50
07/18/19
11:50
General news
Treasury's auctions of $70 B in 4- and 8-week bills were a little sketchy »

Treasury's auctions…

MIRM

Mirum Pharmaceuticals

$0.00

(0.00%)

11:48
07/18/19
07/18
11:48
07/18/19
11:48
Syndicate
Breaking Syndicate news story on Mirum Pharmaceuticals »

Mirum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

YTRA

Yatra

$4.30

-0.09 (-2.05%)

, EBIX

Ebix

$44.40

-0.431 (-0.96%)

11:47
07/18/19
07/18
11:47
07/18/19
11:47
Conference/Events
Yatra and Ebix to hold a joint conference call »

Yatra and Ebix discuss…

YTRA

Yatra

$4.30

-0.09 (-2.05%)

EBIX

Ebix

$44.40

-0.431 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 19

    Jul

AAPL

Apple

$203.94

0.62 (0.30%)

, SWKS

Skyworks

$79.97

-0.18 (-0.22%)

11:46
07/18/19
07/18
11:46
07/18/19
11:46
On The Fly
Downgrades of Exxon, AMD among today's top analyst actions »

Check out today's top…

AAPL

Apple

$203.94

0.62 (0.30%)

SWKS

Skyworks

$79.97

-0.18 (-0.22%)

XOM

Exxon Mobil

$74.58

-0.91 (-1.21%)

AMD

AMD

$32.56

-1.03 (-3.07%)

NFLX

Netflix

$321.21

-41.29 (-11.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 30

    Jul

  • 02

    Aug

  • 07

    Aug

WILC

G. Willi-Food

$10.18

(0.00%)

11:43
07/18/19
07/18
11:43
07/18/19
11:43
Hot Stocks
G. Willi-Food announces CFO Amir Kaplan resigns »

G. Willi-Food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIRM

Mirum Pharmaceuticals

$0.00

(0.00%)

11:41
07/18/19
07/18
11:41
07/18/19
11:41
Syndicate
Mirum Pharmaceuticals indicated to open at $15.00, IPO priced at $15.00 »

Mirum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

11:35
07/18/19
07/18
11:35
07/18/19
11:35
General news
4-Week Bill Auction Total Amount data reported »

4-Week Bill Auction Total…

11:35
07/18/19
07/18
11:35
07/18/19
11:35
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

KERN

Akerna

$13.25

-0.45 (-3.28%)

11:34
07/18/19
07/18
11:34
07/18/19
11:34
Hot Stocks
Akerna announces partnership agreement with Leafly »

Akerna Corp. and Leafly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSM

TSMC

$42.44

0.82 (1.97%)

11:30
07/18/19
07/18
11:30
07/18/19
11:30
Options
Vertical call spread buyer in Taiwan Semi opens 6 month position »

Vertical call spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

BKNG

Booking Holdings

$1,871.84

4.82 (0.26%)

11:23
07/18/19
07/18
11:23
07/18/19
11:23
Periodicals
Breaking Periodicals news story on Booking Holdings »

Hedgeye adds Booking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$123.46

-0.2 (-0.16%)

11:20
07/18/19
07/18
11:20
07/18/19
11:20
Options
Put buyer in Investment Grade Corporate Bond ETF »

Put buyer in Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULC

Fulcrum Therapeutics

$0.00

(0.00%)

11:18
07/18/19
07/18
11:18
07/18/19
11:18
Syndicate
Breaking Syndicate news story on Fulcrum Therapeutics »

Fulcrum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.